GenomeFrontier Therapeutics, Inc. is committed to develop state-of-the-art products and platforms for production of next-generation gene-modified cell therapy which is highly effective, specific, persistent, and safe, thus achieving a sustained immune response capable of eradicating diseases.

We do this through our Quantum Engine™, which integrates four proprietary platforms: Quantum Nufect™, Quantum pBac™, iCellar™, and G-Tailor™, for improving vector delivery, therapeutic gene integration with lower size constraints, cell expansion capacity, and gene design effectiveness and efficiency, respectively.